Resumo:
En
|
Texto:
En
|
PDF:
En
Abstract Background: The influences of Oxycodone (OXY) combined with Paclitaxel (PTX) on breast cancer cells are unclear. The present study aimed to examine the effects of OXY combined with PTX on the proliferation, apoptosis, and migration of human breast cancer SKBR3 cells and the underlying mechanism. Methods: The proliferation, apoptosis and invasion of SKBR3 cells were assessed by CCK-8, colony formation assay, flowcytometric, Transwell assay and scratch assays, respectively. In addition, Western blotting was used to detect the expression of related proteins in these cells. The autophagic bodies were observed under a transmission electron microscope. Results: OXY (0.25, 0.5 and 1 mM) significantly inhibited the viability, colony-forming, migration, and invasion of SKBR3 cells as compared to the control group. Furthermore, OXY (0.25, 0.5 and 1 mM) markedly induced the apoptosis of SKBR3 cells and the levels of apoptosis-related proteins. In addition, OXY (0.25, 0.5 and 1 mM) and PTX inhibited the proliferation of SKBR3 cells synergistically as compared to PTX group in vitro. Moreover, OXY (0.25, 0.5 and 1 mM) significantly elevated the PTX-induced apoptosis in SKBR3 cells via downregulating the expression of N-cadherin, Becline-1 LC3-II, p-Akt and p-mTOR and upregulating E-cadherin expression. Compared with the control group, OXY (1 mM) treatment induced autophagy in SKBR3 cells. Conclusions: The present study indicates that OXY can enhance the antitumor effect of PTX on breast cancer in vitro. Hence, the combination of OXY with PTX may serve as a potential strategy for the treatment of breast cancer. Background (OXY (PTX unclear SKBR mechanism Methods CCK8, CCK8 CCK 8, 8 CCK-8 flowcytometric assays respectively addition microscope Results 0.25, 025 0 25 (0.25 05 5 0. mM viability colonyforming, colonyforming forming, forming colony-forming Furthermore apoptosisrelated vitro Moreover PTXinduced Ncadherin, Ncadherin N cadherin, cadherin N-cadherin Becline1 Becline Becline- LC3II, LC3II LCII LC3 II, II LC LC3-II pAkt p Akt pmTOR mTOR Ecadherin E ( Conclusions Hence CCK- 0.25 02 2 (0.2 0.2 (0. (0